| Metric | Q3-26 | Q3-25 |
|---|---|---|
| Revenue | 32.93 | 32.69 |
| Pretax Income | -1.75 | 2.52 |
| Net Income | -2.48 | 1.93 |
| Diluted EPS | -0.04 | 0.01 |
- Net Income YoY
- -228.6%
Key highlights
- Revenue reached $32.93 million, a marginal increase from $32.69 million in the prior year's third quarter
- Net income shifted from a $1.93 million profit to a $2.48 million loss, representing a year-over-year decline of 228.6%
- Diluted earnings per share fell to a loss of $0.04 compared to a profit of $0.01 in the same period of 2025
- Management reaffirmed full-year 2026 revenue guidance between $100.5 million and $111.0 million
- A regulatory decision on the New Drug Application for F351 in China is anticipated by early 2027
How the Period Went
Gyre Therapeutics reported a marginal revenue increase for the third quarter of 2026, with top-line results reaching $32.93 million compared to $32.69 million in the same period of 2025. Despite the stable revenue performance, the company’s bottom line experienced a significant shift. Gyre moved from a net income of $1.93 million in the prior-year quarter to a net loss of $2.48 million in Q3 2026, representing a year-over-year decline of 228.6%. Diluted earnings per share followed this trend, dropping from $0.01 to a loss of $0.04. The transition to a loss reflects a sharp rise in operating costs that outpaced the modest gains in sales.
Margins and Profitability
The pivot to a net loss was driven by a substantial increase in operating expenditures. Research and development (R&D) costs and general and administrative expenses surged during the quarter, putting pressure on operating margins. Pretax income fell to a loss of $1.75 million, down from a profit of $2.52 million in the previous year. This margin compression occurred as the company accelerated its pipeline development and administrative support functions. While the company maintained its revenue trajectory, the lack of exceptional income items to offset these rising costs resulted in the negative earnings profile observed during this period.
Business Overview
Gyre Therapeutics is a clinical-stage biotechnology company primarily focused on developing and commercializing transformative therapies for organ fibrosis and inflammatory diseases. Its core geographic focus is the Chinese market, where it operates through its majority-owned subsidiary. The company's lead product candidate, F351 (hydronidone), is currently under review by the China National Medical Products Administration (NMPA) for the treatment of chronic hepatitis B (CHB)-induced liver fibrosis. This focus on high-prevalence chronic conditions positions Gyre within a specialized niche of the global healthcare sector, aiming to address significant unmet medical needs in hepatology and respiratory health.
Financial Context
The Q3 results come at a volatile time for Gyre’s market performance. The company’s stock price of $4.01 reflects a significant monthly decline of 43.36%, with the Relative Strength Index at 27.2, placing the security in oversold territory according to technical indicators. Despite the current quarterly net loss, the company’s year-to-date revenue growth remains consistent with its full-year 2026 guidance of $100.5 million to $111.0 million, as reported by company investor relations. The current market capitalization of approximately $462.4 million reflects investor caution regarding the timing of regulatory approvals and the ongoing costs associated with clinical development for its leading therapeutic candidates.
Up 9.5% since our story on 6 Nov: $4.01 when we broke it → $4.39 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $6.09 |
|---|---|
| 20 Oct | $6.17 |
| 21 Oct | $5.90 |
| 22 Oct | $5.86 |
| 23 Oct | $5.85 |
| 26 Oct | $6.07 |
| 27 Oct | $6.53 |
| 28 Oct | $7.09 |
| 29 Oct | $6.41 |
| 30 Oct | $4.56 |
| 2 Nov | $4.73 |
| 3 Nov | $4.44 |
| 4 Nov | $4.44 |
| 5 Nov | $4.01 |
| 6 Nov | $4.76 |
| 9 Nov | $4.65 |
| 10 Nov | $4.23 |
| 11 Nov | $4.26 |
| 12 Nov | $4.30 |
| 13 Nov | $4.31 |
| 16 Nov | $4.39 |
Industry Landscape
The biotechnology sector remains characterized by high capital intensity and regulatory uncertainty, particularly for companies focused on the Chinese market. Peers in the fibrosis space face similar challenges regarding long clinical timelines and stringent regulatory requirements. While broader market conditions for healthcare have seen fluctuations, Gyre’s focus on CHB-induced liver fibrosis addresses a demographic specific to East Asia, distinguishing it from Western-centric biotech firms. The anticipated regulatory decision on F351 by early 2027 is a critical milestone that will likely determine the company's competitive standing against both domestic Chinese biopharmaceutical firms and international players seeking entry into the region.
| Date | Announcement | Amount |
|---|---|---|
| 05 Nov 2026 | Q3 2026 revenueSource: streetinsider.com | $32.9 Million |
| 07 Aug 2026 | Q2 2026 revenueSource: ir.gyretx.com | $29.1 Million |
| 07 May 2026 | Q1 2026 revenueSource: ir.gyretx.com | $22.5 Million |
| 12 Mar 2026 | Q4 2025 revenueSource: ir.gyretx.com | $37.2 Million |
| 07 Nov 2025 | Q3 2025 revenueSource: ir.gyretx.com | $30.6 Million |
| 11 Aug 2025 | Q2 2025 revenueSource: ir.gyretx.com | $26.8 Million |
| Share price | $4.01 |
|---|---|
| Market cap | $462M |
| Revenue (annual) | $117M |
| 1-month price change | -43.36% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Quarterly report filed with the SEC by Gyre Therapeutics, Inc. for the period ending September 30, 2026.
Track GYRE THERAPEUTICS, INC. live
Get the next GYRE THERAPEUTICS, INC. SEC filing seconds after it lands.



